We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement
Analytical Cannabis Logo
×

Home > News > Science & Health

Cannabics Bolsters Team to Develop Cannabinoid Treatments for Cancer

Published: May 23, 2018   

Complete the form below and we will email you a PDF version of "Cannabics Bolsters Team to Develop Cannabinoid Treatments for Cancer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Analytical Cannabis?

Analytical Cannabis Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cannabics Bolsters Team to Develop Cannabinoid Treatments for Cancer

Cannabics Pharmaceuticals has announced the appointment of Haleli Sharir, Ph.D. as principal scientist and Nir Kfir, Ph.D. as senior scientist. The two new team members will support Cannabics' data-discovery process with the goal of identifying new cannabinoid diagnostic tests and treatments for cancer.


Dr. Sharir is widely recognized for her role in identifying a potentially new cannabinoid receptor, GPR55. She was a member of a research group responsible for discovering that human GPR55 is activated by several types of cannabinoids. Dr. Sharir has published nine peer-reviewed research papers on the topic. The research was funded by the National Institute of Health (NIH/NIDA), and results are available through the National Center for Biotechnology Information (NCBI).


Dr. Sharir is also proficient in the development, optimization and implementation of high-throughput screening (HTS) and high-content screening (HCS) assessments – approaches to cell biology that are used for large-scale applications.


Dr. Kfir has a background in molecular genetics and specializes in RNA processing and chromatin organization. His previous work has focused on HTS and on researching new chemotherapy treatments that restore a cancer cell's ability to undergo "programmed cell death".


"Dr. Sharir and Dr. Kfir's experience will effectively guide Cannabics' data discovery process and will streamline our compound screenings," said Cannabics Pharmaceuticals Co-Founder and CEO Eyal Barad. "The combined expertise of these leading scientists will help us develop and implement HCS analysis to address the effects of cannabinoids on cancer growth."


This article has been republished from materials provided by Cannabics Pharmaceuticals. Note: material may have been edited for length and content. For further information, please contact the cited source.

 

Like what you just read? You can find similar content on the topic tag shown below.

Science & Health

Stay connected with the latest news in cannabis extraction, science and testing

Get the latest news with the FREE weekly Analytical Cannabis newsletter

 
Advertisement